Headquartered in Boston, MA Fiscal year ends December NASDAQ: CUE cuebiopharma.com
Cue Biopharma is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action currently in Phase 2 development for allergic diseases including chronic spontaneous urticaria and food allergy. The company also developed the Immuno-STAT platform, which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is designed to regulate inflammation and drive Treg-mediated tolerance and is advancing towards Phase 1 clinical studies. Cue generates revenue through collaboration and licensing agreements, including a partnership with Boehringer Ingelheim. The company trades on the Nasdaq under the ticker CUE. Updated
The CBOE Volatility Index (VIX) is reversing sharply this Monday morning, spiking more than 7% after weekend negotiations between the U.S. and Iran collapsed following 21 hours of talks, sending the fear…
Cue Biopharma is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders.
The Wall Street consensus 12-month price target for CUE is $88.00.
